The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
have a read on this article where analysts expect earnings to go and where they have been going..
https://uk.finance.yahoo.com/news/know-beyond-why-gsk-plc-130001598.html
This webpage perhaps gives a more realistic representation of the current GSK Yield given that its former annual historic payout of 80p has been cut significantly -
https://www.dividenddata.co.uk/dividend-yield.py?epic=GSK
Mudeford, Yes, LSE have simply used the pre-demerger 80p pa and adjusted it based upon the Consolidation adj of sp from 4 to 5 (because share qty fell from 5 to 4 there was no change in total value). A lazy inaccurate approach.
Thanks for that, yes makes perfect sense :)
From what I can gather, for the time being they seem to be using a “notional” annualised dividend figure of 100p per share for GSK - which gives you the Yield percentages quoted in your post. The number that you have worked out for yourself is nearer the mark, but the 2022 annual dividend is not in fact 65p (4 times 16.25p).
LSE states yield as 7.56%
I understand divi is 16.25p quarterly to equal 65p
By my workings out on an SP of £13.20 this now has a yield of 4.92%
Am I right or am I missing something? Perhaps historic divi?
TIA
16.25p per share payable on Thursday, 6th October.
Is there a dividend payment due this month and how much is it please.
Stick with it gsk ,will have their day . :-).
If we follow your rule of thumb currently almost more than 70% of stocks worldwide trading below 52 weeks low. This is due to lot of external factors affecting the stock markets and almost everyone follows like herds.
I am where I am, sadly. Taking some comfort from rather old news here:
https://www.investments.halifax.co.uk/research-centre/news-centre/article/?id=10733212&type=bsm
and here:
https://www.investments.halifax.co.uk/research-centre/news-centre/article/?id=10534260&type=bsm
This stock is the same price as it was 25 years ago.. the very definition of dead money., another example of bad investment in my opinion.
You were all warned before the split to sell.
Rule of Thumb don’t touch stocks trading below 52week lows which GSK is. wait until after results Feb . You’ll thank me in long run. just watch it
Third quarter 2022 results on Wednesday 2 November.
Do they have a pipeline update in Oct?
i wouldn’t touch GSK, it’s done nothing for decades. Look at AZN, LILLY, ABBVIE, PFE, MERCK. #better options
driftking27, simply another example of corruption (false intentions, non-transparent motives) within the financial area.....Bank of Ireland fined EUR100.50m today by Irish r
Central Bank / Regulator...
Time to top up or not.....?? Seems a good price at the moment or worth waiting a bit longer ????
i think the higher the target means they are helping there clients sell there low positions. Just saying as these high targets are never reached.
gla
...Not my favourite bank... target us at £18. Now really cheap so hopefully moving up from here.
just a load of "he" said "she" said
Interesting. "Lawyers are only accepting claims from people who took brand name Zantac, and generic ranitidine is no longer included in lawsuits." https://www.drugwatch.com/zantac/lawsuits/
Can you really put a limit on the liability here with GSK? Millions of Zantac prescriptions were issued. From perusing a US lawyers website, 'The level of NDMA found in pills is 30,000 times the safe limit of 90uG and NDMA is deliberately used to cause cancer in lab rats as its such a good carcinogen. ' https://www.shouselaw.com/torts/zantac/
US lawyers are looking for people with very common cancers - eventually 50% of the population get cancer, and with a history of using Zantac ... looking over the past mega litigation vioxx and roundup cases - they are still settling them! The Roundup cases with Bayer is the nearest situation to this - the FDA claimed it was safe for 40 years, then, later, there is some evidence of NHL cancer associated with its use, which emerges in meta studies, still debated by Bayer scientists. The multi million jury damages awards start flying and haven't stopped. https://www.youtube.com/watch?v=83y-b7XmS7w
Hopefully she can do something with the share price like she did at S&N before it sinks any further.
Good start . was going to move more money to gdr after their RNS if a larger company looks at low price range of tests . Happy how GSK moving .
Rumour is that Julie Brown will be our new CFO.
https://uk.finance.yahoo.com/news/gsk-poaches-burberry-cfo-create-170600394.html